Omidubicel-onlv
Omisirge is the first cellular therapy approved to treat patients with severe aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in whic
Omisirge is the first cellular therapy approved to treat patients with severe aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in whic
Christy was a nurse in pediatrics for over 12 years. She was training to have a key role in the neonatal unit. But her plans were interrupted in May, 2026.
Christy and her physician husband were enjoying life with their two young children after a recent relocation. One day in early May, her husband noticed unusual bruising on her legs. She was fatigued, but brushed it off as a byproduct of the 12-hour shifts she served in training at the hospital.
Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, Myelodysplastic Syndromes (MDS), Myelofibrosis, Myeloproliferative Neoplasms (MPNs) Dr. Chan received her MD degree from the University of Arizona College of Medicine, Phoenix. She completed an Internal Medicine Residency at the University of Arizona College of Medicine in Tucson, followed by a Hematology/Oncology Fellowship at Moffitt Cancer Center/University of South Florida. Dr. Chan’s clinical interests include myeloid malignancies, specifically myelodysplastic syndrome (MDS) and
Background: A Phase 3 randomized trial compared immunosuppressive therapy immunosuppressive therapy:
Background: Clonal hematopoiesis hematopoiesis: (hi-mat-uh-poy-EE-suss) The process of making blood cells in the bone marrow.
CONFERENCE LOCATION:
Heldrich Hotel
10 Livingston Avenue
New Brunswick, NJ 08901
Parking:
Complimentary hotel valet parking